Keywords: basf, ends, ph, iii, trial, ancrod, stroke

BASF ends Ph III trial of ancrod in stroke after questions raised by safety

Article | 03 April 2000

Print This

BASF Pharma says that it has discontinued a Phase III clinical trial ofits fibrinogen-lowering drug Viprinex (ancrod), which was being ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in